[SCHEDULE 13G] Silexion Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

Silexion Therapeutics Corp disclosed that three reporting persons—Intracoastal Capital, LLC, Mitchell P. Kopin and Daniel B. Asher—may each be deemed to beneficially own 244,771 ordinary shares, representing 9.99% of the class as of close of business on September 17, 2025. The filing explains these shares arise primarily from warrants issued under a Securities Purchase Agreement and notes multiple warrants include blocker provisions that limit exercise to prevent ownership above 9.99% (and 4.99% for one warrant). Voting and dispositive power over the 244,771 shares is reported as shared rather than sole.

Positive

• Disclosure of a material minority stake: Reporting Persons clearly disclose beneficial ownership of 9.99%, improving transparency for investors
• Blocker provisions disclosed: Multiple warrants contain explicit limits on exercise to prevent ownership above 9.99% (and 4.99% for one warrant), reducing likelihood of an immediate control shift

Negative

• None.

Insights

Financial Analyst

TL;DR: A coordinated group disclosed a near-10% stake via warrants with blocker provisions, creating a material minority position without control.

The Reporting Persons disclose potential beneficial ownership of 9.99% based on warrants and issuance under a Securities Purchase Agreement. The position is substantial relative to outstanding shares reported (731,642 shares) and is structured with blocker provisions that cap exercise rights to maintain ownership below specified thresholds. For investors, this filing signals a significant minority stake and potential future dilution dynamics tied to warrant exercise rights, but it does not indicate control or sole voting authority.

Corporate Governance Expert

TL;DR: Reported holdings show shared governance influence but explicit blocker clauses limit unilateral control from warrant exercises.

The Schedule 13G shows shared voting and dispositive power over 244,771 shares rather than sole control. The repeated disclosure of blocker provisions across multiple warrants is a governance mechanism that prevents any single holder or group from exceeding 9.99% (and 4.99% for one warrant), preserving the issuer's ownership structure. The joint filing and the attached certifications suggest the filing is informational and not intended to effect a change in control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Silexion Therapeutics Corp

(Name of Issuer)

Ordinary shares, par value $0.0135 per share

(Title of Class of Securities)

G1281K130

(CUSIP Number)

09/11/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G1281K130

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 244,771.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 244,771.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

244,771.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. G1281K130

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 244,771.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 244,771.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

244,771.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. G1281K130

1

Names of Reporting Persons

INTRACOASTAL CAPITAL, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 244,771.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 244,771.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

244,771.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silexion Therapeutics Corp
(b)	Address of issuer's principal executive offices: 12 Abba Hillel Road, Ramat-Gan, Israel 5250606
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Ordinary shares, par value $0.0135 per share
(e)	CUSIP No.: G1281K130
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on September 11, 2025 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 12, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 81,203 Ordinary Shares, which consisted of (i) 81,000 Ordinary Shares to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 203 Ordinary Shares issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1"), and all such Ordinary Shares represent beneficial ownership of approximately 9.99% of the Ordinary Shares, based on (1) 731,642 Ordinary Shares outstanding as of September 4, 2025, as reported by the Issuer, plus (2) 81,000 Ordinary Shares to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 203 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 81,297 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Ordinary Shares, (II) 162,500 Ordinary Shares issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Ordinary Shares, (III) 162,500 Ordinary Shares issuable upon exercise of a third warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Ordinary Shares and (IV) 32,100 Ordinary Shares issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 4") because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Ordinary Shares. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 519,600 Ordinary Shares. (ii) As of the close of business on September 17, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 244,771 Ordinary Shares, which consisted of (i) 162,500 Ordinary Shares issuable upon exercise of Intracoastal Warrant 2 and (ii) 82,271 Ordinary Shares issuable upon exercise of Intracoastal Warrant 3, and all such Ordinary Shares represent beneficial ownership of approximately 9.99% of the Ordinary Shares, based on (1) 731,642 Ordinary Shares outstanding as of September 4, 2025, as reported by the Issuer, plus (2) 1,392,250 Ordinary Shares issued at the closing of the transaction contemplated by the SPA, (3) 81,500 Ordinary Shares issued to Intracoastal upon exercise of Intracoastal Warrant 1, (4) 162,500 Ordinary Shares issuable upon exercise of Intracoastal Warrant 2 and (5) 82,271 Ordinary Shares issuable upon exercise of Intracoastal Warrant 3. The foregoing excludes (I) 80,229 Ordinary Shares issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Ordinary Shares and (II) 32,100 Ordinary Shares issuable upon exercise of Intracoastal Warrant 4 because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Ordinary Shares. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 357,100 Ordinary Shares.
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 244,771
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 244,771
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	09/17/2025

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	09/17/2025

INTRACOASTAL CAPITAL, LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	09/17/2025

Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

What stake does Intracoastal Capital (and reporting persons) hold in Silexion Therapeutics (SLXNW)?

Each reporting person may be deemed to beneficially own 244,771 ordinary shares, equal to 9.99% of the class as of September 17, 2025.

How were the shares held or acquired by the reporting persons created?

The shares arise from issuance and exercisable warrants issued at closing of a Securities Purchase Agreement dated September 11, 2025 (including Intracoastal Warrant 1–4).

Do the reporting persons have sole voting or dispositive power over these shares?

No; the filing reports 0 sole voting power and 244,771 shared voting power, and the same pattern for dispositive power.

What are the blocker provisions mentioned in the filing?

Certain warrants include provisions preventing exercise to the extent such exercise would cause beneficial ownership to exceed 9.99% (and 4.99% for one warrant).

Does this Schedule 13G indicate an intent to change control of the issuer?

The filed certification states the securities were not acquired for the purpose of changing or influencing control of the issuer.